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OBJECTIVES: To determine differences in compliance of amlo-
dipin and atorvastatin, and their combination either in 2-pill or
single-pill forms. METHODS: Patient’s data about amlodipin
and/or atorvastatin treatment were obtained from a Health
Insurance Company over an 18 month period (January 2006 to
July 2007). The indirect measure of compliance was based on the
tablet count derived from the size and number of packages dis-
pensed during a 200 days review period. The analyzed sample
involved patients using only atorvastatin (7074), amlodipin
(8177), a 2-pill amlodipin and atorvastatin combination (953)
and amlodipin/atorvastatin in a single-pill (262). Compliance
was measured as the percentage of days covered by a given drug.
The compliance of patients using both drugs concomitantly
was calculated as a product of the compliances of both drugs.
We assumed one tablet as a daily dose for both substances.
RESULTS: The mean compliance for patients using atorvastatin
was 83.3% (SD 20.29), amlodipine 85.8% (SD 18.99). In
patients using both drugs in 2-pills, compliance was 74.8% (SD
24.37), and in the group using amlodipin and atorvastatin in one
tablet the compliance was 84.3% (SD 20.54) (p < 0.001). Age
was one of the relevant factors affecting compliance in all medi-
cations. CONCLUSIONS: Patients using both, amlodipine and
atorvastatin, in a single-pill can reach higher compliance com-
pared to patients using both of substances concomitantly. The
results of the Czech pilot project on adherence are consistent
with published literature.
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OBJECTIVES: International databases for prescription and use
of pharmaceuticals suggest that adherence and persistence to
antihypertensive treatment is low and decreasing over time. Fur-
thermore, persistence rates seem to differ between antihyperten-
sive drug classes. The objective of this analysis is to assess the
implications of poor persistence on the cost-effectiveness of alter-
native antihypertensive drug treatments. METHODS: A stochas-
tic Markov model was developed to estimate resource use,
morbidity and mortality as a result of published differences in
persistence rates. All classes of antihypertensives are assumed to
have identical blood-pressure lowering effects, and a given reduc-
tion in blood pressure thus generates identical reductions in the
probability for stroke, myocardial infarction, and congestive
heart failure. Consequently, differences in CV-related morbidity
and mortality are solely driven by differences in persistency rates.
The model employs a lifetime perspective for a 50-year-old
patient in base-case. Patients that discontinue treatment are
assumed to lose the protective drug effect, and transit from a
well-controlled health state to health states associated with mod-
erate or serious hypertension. In the different Markov states
patients experience CV-events subject to event rates calculated on
the basis of data from the literature. RESULTS: In a hypothetical
comparison between two cohorts of 1000 completely persistent
and completely non-persistent 50-year-olds, the model predicts a
reduction of 75 cardiovascular events and generates a maximum
of 0.46 LYG (discounted at 3%). The ICER (per LYG) of ARBs
compared to alternative drug classes, is highest when compared
to ACE-inhibitors (SEK 105,000, €1 = SEK 9.25) and lowest
when compared to thiazides (SEK 68,000). The cost-effectiveness
decreases with increasing start age or diminishing time perspec-
tive. CONCLUSIONS: Model results suggest that differences in
persistence rates have a non-negligible impact on the relative
cost-effectiveness between antihypertensive drug treatments.
Validation of model predictions via real-life epidemiological
studies is warranted.
PCV90
THE CONTRIBUTION OFTHE MEASUREMENT OF
TREATMENT ACCEPTABILITYTO UNDERSTAND PATIENTS’
ADHERENCETO LONG-TERMTREATMENTS. RESULTS FROM A
FEASIBILITY STUDY CONDUCTED WITH IN FINE PHARMA®:
A COMMUNITY-PHARMACY NETWORK DEDICATEDTO
PHARMACOEPIDEMIOLOGICAL SURVEYS
Saussier C1,Van Ganse E2,Augé-Caumon MJ3, Chamba G4,
Marrel A1, Benmedjahed K5, Longin J1
1MAPI, Lyon, France, 2Pierre Wertheimer Hospital, Bron, France,
3USPO, Paris, France, 4Pharmakeion, Lyon, France, 5Mapi Values, Lyon,
France
OBJECTIVES: Post marketing observational surveys allow
investigation of drug utilization in real life settings. However,
studies conducted with the help of physicians face difﬁculties in
assessing the perception of risks and beneﬁts by patients, as well
as in measuring their adherence. Our objective was to assess
positive and negative outcomes of treatment, to measure ad-
herence and to test the concept of treatment acceptability
in a network of pharmacies speciﬁcally developed to conduct
pharmacoepidemiology studies. METHODS: PHARMA® is a
network of 2090 community-pharmacies representative of the
overall 22,610 French pharmacies with respect to geographic
location. Pharmacies belonging to the network had to include 5
to 10 patients. For each dispensing of statin, pharmacists com-
pleted a dispensing form and patients completed a self-report
questionnaire describing their adherence, their perception
towards the treatment and its side-effects and how acceptable
they considered taking their statin treatment. RESULTS: Among
the 443 patients analysed, 66% of them considered themselves
as adherent to their lipid-lowering therapy, and nearly 60%
reported at least one adverse event mainly muscular pain or
cramps and gastro-intestinal disorders. About 90% of patients
declared never having stopped their treatment because they con-
sidered it more harmful than beneﬁcial. Sixty-six percent of
adherent patients and 42% of non adherent patients agree their
treatment give them more advantages than inconveniences.
About 70% of adherent and 49% of non adherent patients
considered their treatment as “very acceptable”. Our sample was
representative of patients taking statins. CONCLUSIONS: The
pilot survey highlighted a good participation of pharmacists,
along with a good quality of the patient data recorded in phar-
macies. Performing pharmacy-based pharmaco-epidemiological
studies is powerful, effective, and reliable with In ﬁne
PHARMA®. Our study conﬁrmed the potential contribution of
the concept of treatment acceptability to the explanation of
patients’ adherence toward long-term treatment.
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